Catridecacog

Catridecacog (brand name Tretten) is a class of recombinant factor XIII A-subunit based medication, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014.

[2]

[3]

Template:Pharma-stub